Cosmos Holdings (COSM) AI Stock Analysis

• Market Cap: $20.93M
• Dividend Yield: N/A
• Average Volume (3M): 1.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.10
• Shares Outstanding: 31,013,876
• 10 Day Avg. Volume: 1,246,475
• 30 Day Avg. Volume: 1,183,471
• PEG Ratio: 0.02
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 0.24
• P/FCF Ratio: -1.57
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: 0.49
• Enterprise Value/Gross Profit: 4.98
• Enterprise Value/Ebitda: -2.16
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $1.00 ▲(36.99% Upside)

Cosmos Holdings' overall stock score is primarily impacted by its weak financial performance and negative valuation metrics. The technical analysis indicates bearish momentum, further weighing down the score. The absence of earnings call data and corporate events leaves these areas unaddressed in the evaluation.

Cosmos Holdings Business Overview & Revenue Model

Company Description

Cosmos Holdings (COSM) is a global pharmaceutical and wellness company specializing in the distribution of nutraceutical and pharmaceutical products. The company operates primarily within the healthcare sector, focusing on natural supplements, vitamins, and various over-the-counter products. With a commitment to enhancing the quality of life, Cosmos Holdings aims to provide high-quality, innovative health solutions to consumers and professionals across various markets.

How the Company Makes Money

Cosmos Holdings generates revenue through multiple streams, primarily through the sale of its proprietary nutraceutical and pharmaceutical products. The company distributes these products to a wide array of customers, including pharmacies, health food stores, and online platforms. Additionally, Cosmos Holdings leverages strategic partnerships with manufacturers and suppliers to expand its product offerings and market reach. The company also engages in direct-to-consumer sales, enhancing its revenue through e-commerce channels. Moreover, its focus on research and development allows it to introduce new products that meet emerging consumer demands, further contributing to its earnings.

Cosmos Holdings Financial Statement Overview

Summary

Cosmos Holdings faces significant challenges in profitability and cash flow management, despite some revenue growth. The balance sheet shows moderate leverage and a stable asset structure, but ongoing losses impact overall financial health. The company needs to focus on improving margins and cash flow to enhance financial stability.

Income Statement

Cosmos Holdings shows a slight revenue growth in the TTM period, but profitability metrics such as net profit margin and EBIT margin are negative, indicating ongoing losses. The gross profit margin is low, suggesting limited pricing power or high cost of goods sold. Overall, the income statement reflects challenges in achieving profitability despite revenue growth.

Balance Sheet

The company's debt-to-equity ratio has improved over time, indicating better leverage management, but remains moderate. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is stable, suggesting a balanced asset structure. The balance sheet shows some stability but highlights the need for improved profitability.

Cash Flow

Operating cash flow and free cash flow are negative, indicating cash outflows from operations. The free cash flow to net income ratio is positive, suggesting some efficiency in converting earnings to cash, but overall cash flow metrics highlight liquidity challenges. The cash flow statement underscores the need for better cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	55.09M	54.43M	53.38M	50.35M	56.24M	55.41M
Gross Profit	5.42M	4.31M	4.35M	5.96M	8.33M	8.06M
EBITDA	-12.51M	-13.92M	-17.06M	-8.90M	-3.82M	4.39M
Net Income	-15.37M	-16.18M	-18.54M	-13.83M	-7.96M	820.79K
Balance Sheet
Total Assets	61.84M	54.31M	66.01M	68.04M	49.43M	43.84M
Cash, Cash Equivalents and Short-Term Investments	685.77K	336.25K	3.85M	20.76M	293.18K	851.19K
Total Debt	15.65M	11.82M	12.42M	12.03M	27.12M	33.60M
Total Liabilities	35.60M	29.78M	29.97M	28.38M	45.05M	48.01M
Stockholders Equity	26.23M	24.53M	36.04M	39.66M	4.38M	-4.16M
Cash Flow
Free Cash Flow	-5.77M	-8.14M	-24.80M	-15.25M	-7.99M	-11.62M
Operating Cash Flow	-4.49M	-7.72M	-15.64M	-14.87M	-7.10M	-11.50M
Investing Cash Flow	-975.92K	-798.27K	-13.76M	-21.50K	-826.82K	-117.74K
Financing Cash Flow	6.47M	5.05M	12.69M	35.05M	7.27M	12.46M

Cosmos Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Neutral. The current price of 0.73 is below the 20-day moving average (MA) of 0.92, below the 50-day MA of 0.94, and above the 200-day MA of 0.65, indicating a neutral trend. The MACD of -0.08 indicates Positive momentum. The RSI at 36.81 is Neutral, neither overbought nor oversold. The STOCH value of 13.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COSM.

Cosmos Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AYTU	50 Neutral	$21.11M	-0.76	-60.76%	―	-18.05%	33.87%
RMTI	47 Neutral	$33.93M	―	-8.65%	―	-6.79%	61.56%
TXMD	47 Neutral	$13.54M	-29.32	-1.98%	―	156.93%	92.75%
PRPH	45 Neutral	$12.12M	-0.19	―	―	―	―
COSM	41 Neutral	$20.93M	-0.68	-52.69%	―	―	―
SCYX	41 Neutral	$26.45M	-1.11	-53.29%	―	-65.77%	38.61%

Cosmos Holdings Corporate Events

Cosmos Holdings Appoints Theodoros Karkantzos to Board

On September 30, 2025, Cosmos Health Inc. appointed Theodoros C. Karkantzos as a member of its Board of Directors and the Nominating and Corporate Governance Committee. Mr. Karkantzos, who has over 15 years of experience in investment and business development, was elected at the annual general meeting of stockholders. His expertise includes finance, strategy, private equity, and asset management, and he holds distinguished academic qualifications from the University of Cambridge and the University of Warwick. The appointment is expected to enhance the company’s strategic direction, leveraging Mr. Karkantzos’s extensive experience in various sectors, including real estate and healthcare.

The most recent analyst rating on (COSM) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cosmos Holdings stock, see the COSM Stock Forecast page.

Cosmos Holdings Approves Share Increase at Annual Meeting

At the 2025 Annual Meeting of Stockholders held on September 30, 2025, Cosmos Holdings‘ stockholders approved an amendment to the company’s Articles of Incorporation, increasing the number of authorized shares to 1.5 billion shares of common stock and 300 million shares of preferred stock. This decision, along with the election of directors and approval of various proposals, signifies a strategic move to enhance the company’s capital structure and governance, potentially impacting its market operations and shareholder value.

The most recent analyst rating on (COSM) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cosmos Holdings stock, see the COSM Stock Forecast page.

Cosmos Holdings Secures $8M Convertible Note Agreement

Cosmos Health Inc. has entered into a Securities Purchase Agreement with an institutional investor, resulting in the issuance of a 9% original issue discount senior secured convertible promissory note worth $8,000,000. This transaction, completed on August 7, 2025, was conducted as a private offering under an exemption from registration. The note, maturing on August 7, 2027, allows for conversion into common stock and includes a beneficial ownership limitation to prevent the purchaser from owning more than 4.99% of the company’s outstanding shares. The note ranks senior to all other company debt, excluding permitted indebtedness.